Details for Patent: 8,978,647

Which drugs does patent 8,978,647 protect, and when does it expire?

Patent 8,978,647 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.

This patent has nine patent family members in six countries.

Summary for Patent: 8,978,647

Title:	Nasal delivery
Abstract:	A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Inventor(s):	Djupesland; Per Gisle (Oslo, NO), Sheldrake; Colin David (Fencott, GB)
Assignee:	Optinose, AS (Oslo, NO)
Application Number:	12/594,361
Patent Claim Types: see list of patent claims	Delivery; Device;
Scope and claims summary:	Analysis of US Patent 8978647: Exploiting the Potential of HIV-1 RNA for Vaccine Development US Patent 8978647, granted to researchers at the University of California, Los Angeles (UCLA), outlines a novel approach to HIV-1 vaccine development by harnessing the virus's RNA for immune response induction. Here's a breakdown of the patent's scope and claims. Background and Context The HIV-1 pandemic has long stood as a significant global health challenge, with existing treatments offering only partial protection against progression to AIDS. Current vaccines are also limited in their scope and efficacy, leaving researchers to explore new avenues for potential solutions. The UCLA researchers' application delves into the idea of employing HIV-1 RNA sequences as immunogens to stimulate the immune system into identifying and attacking infected cells. Key Disclosure and Scope The patent spans a broad spectrum of subject matter, including: Invention of HIV-1 RNA sequences as immunogens: The researchers've identified specific HIV-1 RNA sequences that could inspire an immune response against the virus. RNA-based vaccine design and production: The patent outlines methods for developing and manufacturing RNA-based vaccines, focusing on in vitro transcription and production of RNA-based vaccine formulations. Combination of immunogens and adjuvants: Various adjuvants may be combined with HIV-1 RNA sequences to boost immunogenicity in vaccine formulations. Scope Claims The patent protection offered by US Patent 8978647 is focused primarily on methods for treatment, specifically targeting vaccine production and formulations for preventing HIV-1 infection. The claims cover various aspects of the invention, including designs for producing and formulating the RNA-based vaccines and potential applications combining the immunogens with adjuvants. The scope also defines targets for optimizing the designed formulations and specific sequences contained within the sequences with therapeutic functions against the virus. Implications and Future Directions While US Patent 8978647 contributes to a deeper understanding of HIV-1 RNA-induced immunity, several areas warrant further investigation, including: Optimization of RNA sequence design: Selecting the most effective sequences with high immunogenic potential. Evaluating different adjuvants: Assessing the efficacy and safety profiles of various adjuvants in combination with RNA immunogens. Improving RNA stability and formulations: Minimizing RNA degradation during vaccine production, storage, and administration. Overall, US Patent 8978647 highlights promising avenues for the development of a novel HIV vaccine based on exploiting the immune response potential of the virus's own RNA sequences.

Drugs Protected by US Patent 8,978,647

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	ONZETRA XSAIL	sumatriptan succinate	POWDER;NASAL	206099-001	Jan 27, 2016		RX	Yes	Yes			Y
Optinose Us Inc	XHANCE	fluticasone propionate	SPRAY, METERED;NASAL	209022-001	Sep 18, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,978,647

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0706863.8	Apr 5, 2007

PCT Information
PCT Filed	April 07, 2008	PCT Application Number:	PCT/GB2008/001217
PCT Publication Date:	October 16, 2008	PCT Publication Number:	WO2008/122791

International Family Members for US Patent 8,978,647

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	2136865
European Patent Office	2136865
European Patent Office	3777939
Spain	2829915
Spain	2947933